41,789 Shares in Hinge Health Inc. $HNGE Bought by Vista Investment Partners LLC

Vista Investment Partners LLC bought a new stake in shares of Hinge Health Inc. (NYSE:HNGE) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 41,789 shares of the company’s stock, valued at approximately $3,468,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC grew its position in Hinge Health by 3.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock worth $362,000 after purchasing an additional 300 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Hinge Health by 160.0% in the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock worth $25,000 after buying an additional 336 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Hinge Health by 0.6% in the first quarter. Lazard Asset Management LLC now owns 63,705 shares of the company’s stock worth $2,456,000 after buying an additional 386 shares during the last quarter. First Horizon Corp grew its holdings in Hinge Health by 163.9% during the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after acquiring an additional 531 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Hinge Health during the fourth quarter valued at approximately $26,000.

Hinge Health Trading Down 0.3%

Shares of HNGE opened at $89.04 on Monday. The firm has a market cap of $6.89 billion, a P/E ratio of 69.56 and a beta of 1.31. Hinge Health Inc. has a 12 month low of $30.08 and a 12 month high of $91.50. The stock’s 50 day moving average is $76.22 and its two-hundred day moving average is $55.01.

Hinge Health (NYSE:HNGE) last announced its earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.31. Hinge Health had a return on equity of 65.44% and a net margin of 15.15%.The business had revenue of $212.82 million during the quarter. During the same period in the previous year, the company earned $0.59 earnings per share. The company’s quarterly revenue was up 53.0% compared to the same quarter last year. Equities research analysts forecast that Hinge Health Inc. will post 1.37 EPS for the current year.

Insider Transactions at Hinge Health

In other Hinge Health news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $60.22, for a total transaction of $5,018,373.48. Following the completion of the sale, the chairman directly owned 83,334 shares in the company, valued at approximately $5,018,373.48. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Insight Holdings Group, Llc sold 1,466,667 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $82.83, for a total value of $121,484,027.61. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,715,194 shares of company stock worth $287,886,932 over the last ninety days. 18.92% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on HNGE. Stifel Nicolaus set a $96.00 price target on Hinge Health in a report on Wednesday. Wells Fargo & Company lifted their target price on shares of Hinge Health from $90.00 to $103.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Truist Financial boosted their target price on shares of Hinge Health from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Raymond James Financial increased their price target on shares of Hinge Health from $70.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, KeyCorp lifted their price objective on shares of Hinge Health from $90.00 to $125.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.64.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.